Melanoma is an immunogenetic tumor with defined tumor antigens. An important therapeutic aim is the induction of anti-melanoma specific cytotoxic T-lymphocytes (CTL). Dendritic cells (DC) as natur's adjuvant have proven to be suitable for the inducation of anti-melanoma specific CTL in several murinemodels. We will discuss curent issues in the use of DC for treatment of human cancer such as the generation and application of human DC, use of surrogate helper antigens, various methods to detect antigen-specific immune response and briefly touch on some of our clinical data relating to vaccination of stage IV melanoma patients. Finally, we will propose reasons for missing response to DC therapy.

Rights

URN

URN:NBN:SI:DOC-HBN855ND

COBISSID

10734297

Added

12.12.2023

Metadata

Citation

APA:

Nestle, Frank O. (1999). Ocena rezultatov vakcinacije z dendritičnimi celicami pri zdravljenju raka priljudeh. Radiology and oncology (Ljubljana), volume 33, suppl. 1, str. S64-8. URN:NBN:SI:DOC-HBN855ND from http://www.dlib.si

MLA:

Nestle, Frank O.. "Ocena rezultatov vakcinacije z dendritičnimi celicami pri zdravljenju raka priljudeh." Radiology and oncology (Ljubljana) volume 33. suppl. 1 (1999) str. S64-8.
<http://www.dlib.si/?URN=URN:NBN:SI:DOC-HBN855ND>

Radiology and oncology
1992-
(Assembly record)

prejšnja

Epiluminiscenčna mikroskopija v diagnostiki nejasnih melanocitnih kožnih spreemb: primerjava dermatoskopskih ABCD pravil z novo sedem točkovno listo preverjanja, ki temelji na analizi vzorcev
1999
(Previous issue)

Ocena rezultatov vakcinacije z dendritičnimi celicami pri zdravljenju raka priljudehCritical issues regarding dendritic cell vaccination for human cancer

Ocena rezultatov vakcinacije z dendritičnimi celicami pri zdravljenju raka priljudeh
Critical issues regarding dendritic cell vaccination for human cancer